TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Beats Estimates By $0.01 EPS

TuHURA Biosciences (NASDAQ:HURA) announced its quarterly earnings results on Friday. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01, FiscalAI reports.

TuHURA Biosciences Stock Performance

Shares of NASDAQ HURA traded up $0.17 during trading on Friday, reaching $2.47. The company had a trading volume of 317,089 shares, compared to its average volume of 1,079,055. TuHURA Biosciences has a 52 week low of $0.41 and a 52 week high of $3.43. The business’s 50 day moving average price is $2.27 and its 200-day moving average price is $2.00. The stock has a market cap of $157.30 million, a PE ratio of -4.05 and a beta of -0.01.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Bank of America Corp DE acquired a new stake in shares of TuHURA Biosciences in the 4th quarter valued at $59,000. Jane Street Group LLC acquired a new stake in TuHURA Biosciences in the first quarter worth about $69,000. Geode Capital Management LLC grew its position in shares of TuHURA Biosciences by 111.4% during the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after buying an additional 307,260 shares during the period. JPMorgan Chase & Co. bought a new stake in shares of TuHURA Biosciences during the second quarter worth approximately $27,000. Finally, New York State Common Retirement Fund bought a new stake in shares of TuHURA Biosciences during the 2nd quarter valued at $97,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Friday, July 17th. Citizens Jmp assumed coverage on TuHURA Biosciences in a research report on Monday, April 27th. They set a “market outperform” rating and a $9.00 target price on the stock. Citigroup initiated coverage on TuHURA Biosciences in a report on Monday, April 27th. They set an “outperform” rating on the stock. Finally, Wall Street Zen lowered TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, May 31st. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.